Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:36 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
NCT04729387 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2026-10-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor Decision” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, Abemaciclib + PI3K Inhibitor paxalisib (NCT03994796)
- 2026-10-27Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Ipilimumab (NCT04317105)
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-09-10Also stopped (terminated): Novartis Pharmaceuticals, alpelisib + placebo (NCT04251533)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-07Results posted on the registry: M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-07-07Also stopped (terminated): M.D. Anderson Cancer Center, Alpelisib + Nab-paclitaxel (NCT04216472)
- 2026-06-25Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT05631795)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Rituximab + Copanlisib (NCT03789240)
- 2026-02-13Also stopped (suspended): Dana-Farber Cancer Institute, Palbociclib + Gedatolisib (NCT03065062)
- 2026-02-09Also stopped (withdrawn): Hoffmann-La Roche, Inavolisib + Bevacizumab (NCT07323576)
- 2026-02-04Also stopped (terminated): Centre Hospitalier Universitaire Dijon, Taselisib (GDC0032) + Taselisib (GDC0032) (NCT03290092)
- 2026-01-22Results posted on the registry: Jennifer Lee Caswell-Jin, Alpelisib + Tamoxifen (NCT05101564)
- 2026-01-09Also stopped (terminated): M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision